{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:10:56Z","timestamp":1790813456577,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Immunotherapy has become widely applied in non-small cell lung cancer (NSCLC) patients. However, the relatively low response rate of immunotherapy monotherapy restricts its application. Combination therapy improves the response rate and prolongs patient survival; however, adverse events (AEs) associated with immunotherapies increase with combination therapy. Therefore, exploring combination regimens with equal efficacy and fewer AEs is urgently required. The aim of this study was to evaluate the efficacy and safety of microwave ablation (MWA) plus camrelizumab monotherapy or combination therapy in NSCLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Patients with pathologically confirmed, epidermal growth factor receptor\/anaplastic lymphoma kinase-wild-type NSCLC were retrospectively enrolled in this study. Patients underwent MWA to the pulmonary lesions first, followed by camrelizumab monotherapy or combination therapy 5\u20137 days later. Camrelizumab was administered with the dose of 200 mg every 2 to 3 weeks. Treatment was continued until disease progression or intolerable toxicities. The technical success and technique efficacy of ablation, objective response rate (ORR), progression-free survival (PFS), overall survival (OS), complications of ablation, and AEs were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From January 1, 2019 to December 31, 2021, a total of 77 patients underwent MWA and camrelizumab monotherapy or combination therapy. Technical success was achieved in all patients (100%), and the technique efficacy was 97.4%. The ORR was 29.9%. The PFS and OS were 11.8 months (95% confidence interval, 9.5\u201314.1) and not reached, respectively. Smoking history and response to camrelizumab were correlated with PFS, and response to camrelizumab was correlated with OS in both the univariate and multivariate analyses. No periprocedural deaths due to ablation were observed. Complications were observed in 33 patients (42.9%). Major complications included pneumothorax (18.2%), pleural effusion (11.7%), pneumonia (5.2%), bronchopleural fistula (2.6%), and hemoptysis (1.3%). Grade 3 or higher AEs of camrelizumab, including reactive capillary endothelial proliferation, fatigue, pneumonia, edema, and fever, were observed in 10.4%, 6.5%, 5.2%, 2.6%, and 2.6% of patients, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MWA combined with camrelizumab monotherapy or combination therapy is effective and safe for the treatment of NSCLC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.938827","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T10:03:47Z","timestamp":1661508227000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Yahan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pikun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and united states, 2022: Profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4065\/83.5.584","article-title":"Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clinic Proc"},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The iaslc lung cancer staging project: Proposals for revision of the tnm stage groupings in the forthcoming (Eighth) edition of the tnm classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet (London England)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/op.21.00305","article-title":"Advances in immunotherapy and implications for current practice in non-Small-Cell lung cancer","volume":"17","author":"Steuer","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for pd-L1-Positive non-Small-Cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, pd-L1-Expressing, locally advanced or metastatic non-Small-Cell lung cancer (Keynote-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet (London England)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of pd-L1-Selected patients with nsclc","volume":"383","author":"Herbst","year":"2020","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-Small-Cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-Small-Cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"New Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-Small-Cell lung cancer (Impower130): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/s1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-Small-Cell lung cancer (Checkmate 9la): An international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-022-08615-8","article-title":"Microwave ablation treatment for medically inoperable stage I non-small cell lung cancers: Long-term results","volume":"32","author":"Ni","year":"2022","journal-title":"Eur Radiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25259\/jcis_224_2020","article-title":"Computerized tomography-guided microwave ablation of patients with stage I non-small cell lung cancers: A single-institution retrospective study","volume":"11","author":"Nance","year":"2021","journal-title":"J Clin Imaging Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.08.142","article-title":"Percutaneous thermal ablation for stage ia non-small cell lung cancer: Long-term follow-up","volume":"9","author":"Narsule","year":"2017","journal-title":"J Thorac Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-019-06613-x","article-title":"Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: A multicenter, randomized, controlled, phase iii clinical trial","volume":"30","author":"Wei","year":"2020","journal-title":"Eur Radiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03176-z","article-title":"Microwave ablation for non-small cell lung cancer with synchronous solitary extracranial metastasis","volume":"146","author":"Ni","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12032-015-0672-1","article-title":"Targeted percutaneous microwave ablation at the pulmonary lesion combined with mediastinal radiotherapy with or without concurrent chemotherapy in locally advanced non-small cell lung cancer evaluation in a randomized comparison study","volume":"32","author":"Xu","year":"2015","journal-title":"Med Oncol (Northwood London England)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_990_19","article-title":"Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer","volume":"15","author":"Wei","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.14132958","article-title":"Image-guided tumor ablation: Standardization of terminology and reporting criteria\u2013a 10-year update","volume":"273","author":"Ahmed","year":"2014","journal-title":"Radiology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised recist guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2009.04.035","article-title":"Society of interventional radiology clinical practice guidelines","volume":"20","author":"Cardella","year":"2009","journal-title":"J Vasc intervent Radiol JVIR"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.02.004","article-title":"Phase ii trial of combination nab-paclitaxel and gemcitabine in non-squamous non-small cell lung cancer after progression on platinum and pemetrexed","volume":"23","author":"Ciunci","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-Small-Cell lung cancer (Camel): A randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous nsclc (Camel-sq): A phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-3136","article-title":"Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous nsclc previously treated with chemotherapy","volume":"27","author":"Zhou","year":"2021","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.628124","article-title":"Efficacy and safety of anti-Pd-1 plus anlotinib in patients with advanced non-Small-Cell lung cancer after previous systemic treatment failure-a retrospective study","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0013","article-title":"Nccn guidelines insights: Non-small cell lung cancer, version 2.2021","volume":"19","author":"Ettinger","year":"2021","journal-title":"J Natl Compr Cancer Network JNCCN"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2019.1642522","article-title":"Efficacy and safety of microwave ablation in the treatment of patients with oligometastatic non-Small-Cell lung cancer: A retrospective study","volume":"36","author":"Wei","year":"2019","journal-title":"Int J hyperthermia Off J Eur Soc Hyperthermic Oncol North Am Hyperthermia Group"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01404-y","article-title":"Multicentre study of microwave ablation for pulmonary oligorecurrence after radical resection of non-Small-Cell lung cancer","volume":"125","author":"Ni","year":"2021","journal-title":"Br J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0464-z","article-title":"Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone","volume":"32","author":"Wei","year":"2015","journal-title":"Med Oncol (Northwood London England)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-014-0895-0","article-title":"Microwave ablation in combination with chemotherapy for the treatment of advanced non-small cell lung cancer","volume":"38","author":"Wei","year":"2015","journal-title":"Cardiovasc intervent Radiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23701","article-title":"Percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: Clinical evaluation of 47 cases","volume":"110","author":"Yang","year":"2014","journal-title":"J Surg Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13209","article-title":"Safety and clinical outcomes of computed tomography-guided percutaneous microwave ablation in patients aged 80\u2009Years and older with early-stage non-small cell lung cancer: A multicenter retrospective study","volume":"10","author":"Han","year":"2019","journal-title":"Thorac Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.diii.2017.12.011","article-title":"Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model","volume":"99","author":"Zhu","year":"2018","journal-title":"Diagn Interv Imaging"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1352","article-title":"PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor","volume":"22","author":"Shi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013112","article-title":"A case report of remarkable response to association of radiofrequency ablation with subsequent atezolizumab in stage IV nonsmall cell lung cancer","volume":"97","author":"Yin","year":"2018","journal-title":"Med (Baltimore)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.938827\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T10:03:50Z","timestamp":1661508230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.938827\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":39,"alternative-id":["10.3389\/fonc.2022.938827"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.938827","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"article-number":"938827"}}